Freeline Therapeutics Holdings plc (FRLN) NASDAQ
6.49
+0.01(+0.15%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Freeline Therapeutics Holdings plc
Address
Stevenage Bioscience Catalyst
Stevenage, SG1 2FX
United Kingdom of Great Britain and Northern Ireland (the)
Phone
44 14 3890 6870
Website
Sector
Healthcare
Industry
Biotechnology
Employees
152
First IPO Date
August 07, 2020
Key Executives
| Name | Title | Pay | Year Born |
| Michael J. Parini | Chief Executive Officer & Executive Director | 2.16M | 1975 |
| Henning R. Stennicke | Chief Scientific Officer | 0 | 1968 |
| Pamela Foulds | Chief Medical Officer | 0 | 1970 |
| James Bircher | Chief Technical Operations Officer | 0 | 1968 |
| Paul Schneider | Chief Financial Officer & Director | 0 | 1971 |
| Amy J. Spandau | Interim Head of Finance | 0 | 1975 |
| Naomi Aoki | Senior Vice President of Corporation Communications & Investor Relations | 0 | N/A |
| Nicole Jones | Chief People Officer | 0 | 1971 |
Description
Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is verbrinacogene setparvovec (FLT180a), a gene therapy product candidate that is in Phase 1/2 clinical trials in adult males for the treatment of hemophilia B. The company's products also include FLT190, which is in Phase 1/2 clinical trial for the treatment of Fabry disease; and FLT201, a liver-directed gene therapy product candidate to treat type 1 Gaucher disease and is under Phase 1/2 clinical trial. In addition, it has research programs in various indications for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.
